SeaStar Medical Holding Corporation (ICU) - Total Liabilities
Based on the latest financial reports, SeaStar Medical Holding Corporation (ICU) has total liabilities worth $3.74 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SeaStar Medical Holding Corporation net asset momentum to track the company's year-over-year net asset growth rate.
SeaStar Medical Holding Corporation - Total Liabilities Trend (2020–2025)
This chart illustrates how SeaStar Medical Holding Corporation's total liabilities have evolved over time, based on quarterly financial data.
SeaStar Medical Holding Corporation Competitors by Total Liabilities
The table below lists competitors of SeaStar Medical Holding Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanalysis Scientific Corp
V:NSCI
|
Canada | CA$22.05 Million |
|
Schweizer Electronic AG
F:SCE
|
Germany | €93.41 Million |
|
Neometals Ltd
AU:NMT
|
Australia | AU$8.74 Million |
|
Smith Micro Software Inc
NASDAQ:SMSI
|
USA | $7.24 Million |
|
Bayhorse Silver Inc
V:BHS
|
Canada | CA$2.49 Million |
|
Ranix INC
KQ:317120
|
Korea | ₩18.68 Billion |
|
Park & Bellheimer AG
F:PKB
|
Germany | €23.21 Million |
|
Elicera Therapeutics AB
ST:ELIC
|
Sweden | Skr6.97 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down SeaStar Medical Holding Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of SeaStar Medical Holding Corporation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SeaStar Medical Holding Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SeaStar Medical Holding Corporation (2020–2025)
The table below shows the annual total liabilities of SeaStar Medical Holding Corporation from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.74 Million | -45.30% |
| 2024-12-31 | $6.84 Million | -60.65% |
| 2023-12-31 | $17.38 Million | -26.96% |
| 2022-12-31 | $23.80 Million | +596.11% |
| 2021-12-31 | $3.42 Million | -95.41% |
| 2020-12-31 | $74.49 Million | -- |
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperi… Read more